Migraine treatment in homoeopathy
- Conditions
- Health Condition 1: G439- Migraine, unspecified
- Registration Number
- CTRI/2023/05/052590
- Lead Sponsor
- Priyanka Sharma
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Have a history of migraine as defined by the International Headache Society (IHS) International Classification of Headache Disorders II guidelines 1.1 and 1.2 (ICHD-II, Cephalgia 2006) of at least 1 year prior to enrollment, migraine onset prior to age 50, and a moderate frequency of migraine headaches
Have clinical laboratory test results within normal reference ranges or, if outside the normal range, judged not clinically significant by the Investigator
Must not be on any migraine prevention therapy, including botulinum toxin (Botox)
Agree not to post any personal medical data related to the study or information related to the study on any website or social media site (for example, Facebook, Twitter, et cetera) until the trial has completed.
Current enrollment in, or discontinuation within the last 30 days from, a clinical trial involving any investigational drug or device, or concurrent enrollment in any other type of medical research judged not to be scientifically or medically compatible with this study.
History of chronic migraine or migraine subtypes including hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and basilar-type migraine
History of headache (for example, cluster headache or Medication Overuse Headache [MOH]) other than migraine or tension type headache as defined by IHS ICHD-II within 12 months prior to randomization
Evidence of significant active psychiatric disease including, but not limited to, manic depressive illness, schizophrenia, generalized anxiety disorder, obsessive compulsive disorder, personality disorders, or other serious mood, anxiety, depression, or substance use disorders
Women who are pregnant or nursing
Excessive alcohol, opiate, or barbiturate use; history of drug abuse or dependence
Patients who are terminally ill, under immunosuppressive treatment or self-reported immunocompromised state.
Unwilling to take part and not giving consent to join the study or unable to read patient information sheet.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assessment will be done using MIDAS SCALETimepoint: One at the baseline and other at the end of the study
- Secondary Outcome Measures
Name Time Method Depending upon the severity of the symptoms and as per the need and necessity of the caseTimepoint: Every 2 weeks